Peptide Therapeutics Market Report 2026

The peptide therapeutics market size has grown rapidly in recent years. It will grow from $49.21 billion in 2025 to $54.62 billion in 2026 at a compound annual growth rate (CAGR) of 11%. The growth in the historic period can be attributed to early adoption of peptide drugs, development of peptide synthesis techniques, increasing incidence of chronic and rare diseases, advances in pharmacology and biochemistry, growth of contract research organizations.

The peptide therapeutics market size is expected to see rapid growth in the next few years. It will grow to $83.57 billion in 2030 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to rise of personalized medicine, increasing investment in peptide-based therapeutics, integration of AI in drug discovery, expansion of biologics manufacturing, growth in emerging markets for healthcare solutions. Major trends in the forecast period include targeted peptide drug development, peptide drug delivery innovations, multi-functional peptide therapeutics, natural peptide extraction & synthesis, combination therapies with peptides.

The rising prevalence of chronic diseases is expected to drive growth in the peptide therapeutics market. Chronic diseases are long-lasting medical conditions that may not be fully curable but are often manageable with appropriate treatment. Factors such as tobacco use, poor nutrition, physical inactivity, and excessive alcohol consumption contribute to the increasing incidence of chronic diseases. Peptide therapeutics play a key role in the prevention and treatment of certain chronic conditions. For instance, in January 2023, according to the National Library of Medicine, a US-based agency, the number of individuals in the U.S. aged 50 and older with at least one chronic condition is projected to increase by 99.5%, reaching 142.66 million by 2050. Therefore, the growing prevalence of chronic diseases is expected to propel the peptide therapeutics market during the forecast period.

Major companies in the peptide therapeutics market are focusing on advanced solutions such as cell culture processes to gain a competitive advantage. Cell culture processes involve growing cells outside their natural environment under controlled conditions, isolating cells of interest, and maintaining them for various applications. For instance, in June 2023, Evonik Industries AG, a Germany-based specialty chemicals company, launched cQrex KC, a next-generation peptide designed for biopharmaceutical applications in cell culture processes. cQrex KC helps optimize cystine supply, enhance cell culture productivity, and supports the development of vaccines, viral vectors, and cell therapies.

In July 2024, AstraZeneca plc, a UK-based pharmaceutical and biotechnology company, acquired Amolyt Pharma for $1.05 billion. This acquisition strengthens AstraZeneca’s capabilities in rare diseases and expands its therapeutic offerings in high-need areas. Amolyt Pharma, a France-based clinical-stage biotechnology company, specializes in developing therapeutic peptides for the treatment of rare endocrine and metabolic disorders.

Major companies operating in the peptide therapeutics market are Pfizer Inc., Jhonson & Jhonson, Abbvie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Sanofi SA, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk AS, Teva Pharmaceuticals Industries Ltd., Bachem Holding AG, PolyPeptide Laboratories BV, Arcus Biosciences Inc., Pepscan Therapeutics, Peptech Inc., Peptide Logic Inc., SELLAS Life Sciences Group, Ever Neuro Pharma GmbH, Zealand Pharma AG, PepGen Inc., Pepticom S.A., Peptide Technologies Corporation, SynPeptide Inc., Peptimmune Inc., Merck & Co Inc.

North America was the largest region in the peptide therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the peptide therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the peptide therapeutics market by increasing import costs for raw materials and active pharmaceutical ingredients, particularly affecting peptide synthesis and delivery technology segments. Regions such as North America and Europe, which rely on imports from Asia-Pacific manufacturing hubs like China and India, are most impacted. While tariffs raise production costs and slow market expansion, they also incentivize local production, innovation in cost-effective peptide manufacturing, and development of domestic supply chains, providing potential long-term benefits.

The peptide therapeutics market research report is one of a series of new reports that provides peptide therapeutics market statistics, including peptide therapeutics industry global market size, regional shares, competitors with a peptide therapeutics market share, detailed peptide therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the peptide therapeutics industry. This peptide therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Peptide therapeutics refer to a treatment approach that uses peptides as medications. Peptides are a unique class of pharmacological agents that fall between proteins and small molecules in size. Naturally occurring peptides serve multiple functions, including acting as hormones, growth factors, neurotransmitters, ion channel ligands, and anti-infectives. Using peptides as therapeutics provides a way to target specific cells and modulate their responses.

The main types of peptide therapeutics are generic and branded. Branded peptide therapeutics are marketed under the brand names of major pharmaceutical companies that hold the patents, making them more expensive than generic alternatives. These therapeutics can be administered via parenteral, mucosal, oral, and transdermal routes. They are used in the treatment of cancer, cardiovascular diseases, central nervous system disorders, metabolic disorders, infections, hematological conditions, gastrointestinal disorders, dermatological conditions, respiratory disorders, and acromegaly.

The peptide therapeutics market includes revenues earned by entities by creating drugs to treat a variety of diseases. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.